{"pmid":32463087,"title":"Antimicrobial resistance: the good, the bad, and the ugly.","text":["Antimicrobial resistance: the good, the bad, and the ugly.","As the Royal Society for Biology (RSB) was forming 10 years ago, antimicrobial resistance (AMR) was being heralded as the next threat with a magnitude on a par with global warming. Just a few years later, in 2016, Jim O'Neill's report was published laying out recommendations for tackling drug-resistant infections globally. Where are we now, and what are the challenges ahead? As a slow burner, how will the impact of AMR compare against the recent rapid devastation of the COVID-19 pandemic, and how can we channel some of the good things that come from it (like the awareness and technique of effective hand hygiene) to help us combat AMR speedily and definitively?","Emerg Top Life Sci","Hardie, Kim R","32463087"],"abstract":["As the Royal Society for Biology (RSB) was forming 10 years ago, antimicrobial resistance (AMR) was being heralded as the next threat with a magnitude on a par with global warming. Just a few years later, in 2016, Jim O'Neill's report was published laying out recommendations for tackling drug-resistant infections globally. Where are we now, and what are the challenges ahead? As a slow burner, how will the impact of AMR compare against the recent rapid devastation of the COVID-19 pandemic, and how can we channel some of the good things that come from it (like the awareness and technique of effective hand hygiene) to help us combat AMR speedily and definitively?"],"journal":"Emerg Top Life Sci","authors":["Hardie, Kim R"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463087","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1042/ETLS20190194","keywords":["antibiotic","antimicrobial resistance","bacteria","biofilms"],"weight":0,"_version_":1668079521543225344,"score":9.490897,"similar":[{"pmid":32399092,"pmcid":"PMC7217106","title":"Antimicrobial resistance is a global problem - a UK perspective.","text":["Antimicrobial resistance is a global problem - a UK perspective.","Increasingly we are reaching a situation where current antimicrobial medicines are no longer effective for common infections, and antimicrobial resistance (AMR) is becoming a global public health crisis. The reliance on antimicrobials such as antibiotics has become a major issue for both medicine and agriculture, particularly given the slow development of new medicines and pharmaceutical industry investment. The UK government has been working with other international bodies in the search for solutions to the many challenges AMR poses. Herbal medicines may provide a useful modality in the fight against AMR and can work solely or in tandem with current antimicrobial approaches. Recommendations for herbal medicine use during the COVID-19 outbreak have featured in Chinese national guidelines and policies, but UK strategies have no such guidance. More research is urgently needed to explore the biological plausibility and safety of herbal medicines to manage AMR. AMR is universal, affecting anyone and everyone, at any age and in any country. Investigating how such approaches can be integrated into western medicine will be important to elucidate.","Eur J Integr Med","Hu, Xiao-Yang","Logue, Martin","Robinson, Nicola","32399092"],"abstract":["Increasingly we are reaching a situation where current antimicrobial medicines are no longer effective for common infections, and antimicrobial resistance (AMR) is becoming a global public health crisis. The reliance on antimicrobials such as antibiotics has become a major issue for both medicine and agriculture, particularly given the slow development of new medicines and pharmaceutical industry investment. The UK government has been working with other international bodies in the search for solutions to the many challenges AMR poses. Herbal medicines may provide a useful modality in the fight against AMR and can work solely or in tandem with current antimicrobial approaches. Recommendations for herbal medicine use during the COVID-19 outbreak have featured in Chinese national guidelines and policies, but UK strategies have no such guidance. More research is urgently needed to explore the biological plausibility and safety of herbal medicines to manage AMR. AMR is universal, affecting anyone and everyone, at any age and in any country. Investigating how such approaches can be integrated into western medicine will be important to elucidate."],"journal":"Eur J Integr Med","authors":["Hu, Xiao-Yang","Logue, Martin","Robinson, Nicola"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32399092","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.eujim.2020.101136","keywords":["antibiotics","antimicrobial resistance","global health","government response","herbal medicine"],"locations":["GBR","Chinese","GBR","GBR"],"countries":["China","United Kingdom"],"countries_codes":["CHN|China","GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666714494990024705,"score":453.0199},{"pmid":32361747,"pmcid":"PMC7197597","title":"COVID-19, superinfections and antimicrobial development: What can we expect?","text":["COVID-19, superinfections and antimicrobial development: What can we expect?","Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development.","Clin Infect Dis","Clancy, Cornelius J","Nguyen, M Hong","32361747"],"abstract":["Coronavirus disease 2019 (COVID-19) arose at a time of great concern about antimicrobial resistance (AMR). No studies have specifically assessed COVID-19-associated superinfections or AMR. Based on limited data from case series, it is reasonable to anticipate that an appreciable minority of patients with severe COVID-19 will develop superinfections, most commonly pneumonia due to nosocomial bacteria and Aspergillus. Microbiology and AMR patterns are likely to reflect institutional ecology. Broad-spectrum antimicrobial use is likely to be widespread among hospitalized patients, both as directed and empiric therapy. Stewardship will have a crucial role in limiting unnecessary antimicrobial use and AMR. Congressional COVID-19 relief bills are considering antimicrobial reimbursement reforms and antimicrobial subscription models, but it is unclear if these will be included in final legislation. Prospective studies on COVID-19 superinfections are needed, data from which can inform rational antimicrobial treatment and stewardship strategies, and models for market reform and sustainable drug development."],"journal":"Clin Infect Dis","authors":["Clancy, Cornelius J","Nguyen, M Hong"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361747","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/cid/ciaa524","keywords":["covid-19","coronavirus disease 2019","antimicrobial development","antimicrobial resistance","superinfections"],"topics":["Treatment"],"weight":1,"_version_":1666138495521914880,"score":381.16537},{"pmid":32311380,"pmcid":"PMC7165117","title":"Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A Position Paper.","text":["Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A Position Paper.","Antimicrobial resistance (AMR) continues to threaten global health. Although global and national AMR action plans are in place, infection prevention and control is primarily discussed in the context of healthcare facilities with home and everyday life settings barely addressed. As seen with the recent global SARS-CoV-2 pandemic, everyday hygiene measures can play an important role in containing the threat from infectious microorganisms. This position paper has been developed following a meeting of global experts in London, 2019. It presents evidence that home and community settings are important for infection transmission and also the acquisition and spread of AMR. It also demonstrates that the targeted hygiene approach offers a framework for maximizing protection against colonization and infections, thereby reducing antibiotic prescribing and minimizing selection pressure for the development of antibiotic resistance. If combined with the provision of clean water and sanitation, targeted hygiene can reduce the circulation of resistant bacteria in homes and communities, regardless of a country's Human Development Index (overall social and economic development). Achieving a reduction of AMR strains in healthcare settings requires a mirrored reduction in the community. The authors call upon national and international policy makers, health agencies and healthcare professionals to further recognize the importance of targeted hygiene in the home and everyday life settings for preventing and controlling infection, in a unified quest to tackle AMR.","Am J Infect Control","Maillard, Jean-Yves","Bloomfield, Sally F","Courvalin, Patrice","Essack, Sabiha Y","Gandra, Sumanth","Gerba, Charles P","Rubino, Joseph R","Scott, Elizabeth A","32311380"],"abstract":["Antimicrobial resistance (AMR) continues to threaten global health. Although global and national AMR action plans are in place, infection prevention and control is primarily discussed in the context of healthcare facilities with home and everyday life settings barely addressed. As seen with the recent global SARS-CoV-2 pandemic, everyday hygiene measures can play an important role in containing the threat from infectious microorganisms. This position paper has been developed following a meeting of global experts in London, 2019. It presents evidence that home and community settings are important for infection transmission and also the acquisition and spread of AMR. It also demonstrates that the targeted hygiene approach offers a framework for maximizing protection against colonization and infections, thereby reducing antibiotic prescribing and minimizing selection pressure for the development of antibiotic resistance. If combined with the provision of clean water and sanitation, targeted hygiene can reduce the circulation of resistant bacteria in homes and communities, regardless of a country's Human Development Index (overall social and economic development). Achieving a reduction of AMR strains in healthcare settings requires a mirrored reduction in the community. The authors call upon national and international policy makers, health agencies and healthcare professionals to further recognize the importance of targeted hygiene in the home and everyday life settings for preventing and controlling infection, in a unified quest to tackle AMR."],"journal":"Am J Infect Control","authors":["Maillard, Jean-Yves","Bloomfield, Sally F","Courvalin, Patrice","Essack, Sabiha Y","Gandra, Sumanth","Gerba, Charles P","Rubino, Joseph R","Scott, Elizabeth A"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311380","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajic.2020.04.011","locations":["London"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"e_drugs":["Water"],"topics":["Prevention"],"weight":1,"_version_":1666138491284619264,"score":355.95132},{"pmid":32433765,"title":"COVID-19 and the potential long-term impact on antimicrobial resistance.","text":["COVID-19 and the potential long-term impact on antimicrobial resistance.","The emergence of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has required an unprecedented response to control the spread of the infection and protect the most vulnerable within society. Whilst the pandemic has focused society on the threat of emerging infections and hand hygiene, certain infection control and antimicrobial stewardship policies may have to be relaxed. It is unclear whether the unintended consequences of these changes will have a net-positive or -negative impact on rates of antimicrobial resistance. Whilst the urgent focus must be on controlling this pandemic, sustained efforts to address the longer-term global threat of antimicrobial resistance should not be overlooked.","J Antimicrob Chemother","Rawson, Timothy M","Moore, Luke S P","Castro-Sanchez, Enrique","Charani, Esmita","Davies, Frances","Satta, Giovanni","Ellington, Matthew J","Holmes, Alison H","32433765"],"abstract":["The emergence of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has required an unprecedented response to control the spread of the infection and protect the most vulnerable within society. Whilst the pandemic has focused society on the threat of emerging infections and hand hygiene, certain infection control and antimicrobial stewardship policies may have to be relaxed. It is unclear whether the unintended consequences of these changes will have a net-positive or -negative impact on rates of antimicrobial resistance. Whilst the urgent focus must be on controlling this pandemic, sustained efforts to address the longer-term global threat of antimicrobial resistance should not be overlooked."],"journal":"J Antimicrob Chemother","authors":["Rawson, Timothy M","Moore, Luke S P","Castro-Sanchez, Enrique","Charani, Esmita","Davies, Frances","Satta, Giovanni","Ellington, Matthew J","Holmes, Alison H"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433765","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1093/jac/dkaa194","topics":["Prevention"],"weight":1,"_version_":1667342288332783616,"score":228.72478},{"pmid":32358954,"pmcid":"PMC7197596","title":"Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","text":["Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing.","BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.","Clin Infect Dis","Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison","32358954"],"abstract":["BACKGROUND: To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. METHODS: MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. RESULTS: 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus.For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described.For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. CONCLUSIONS: Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required."],"journal":"Clin Infect Dis","authors":["Rawson, Timothy M","Moore, Luke S P","Zhu, Nina","Ranganathan, Nishanthy","Skolimowska, Keira","Gilchrist, Mark","Satta, Giovanni","Cooke, Graham","Holmes, Alison"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32358954","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/cid/ciaa530","keywords":["sars-cov-2","antimicrobial resistance","antimicrobial stewardship"],"locations":["Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495313248256,"score":128.57939}]}